Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
Currentg sp
Medical Oncologist, Professor Frances Boyle AM, Director of the Patricia Ritchie Centre for Cancer Care and Research at Mater Hospital and Professor of Medical Oncology at the University of Sydney, said: "We are very pleased to be the first hospital in Australia to have the Steriwave nasal decolonization system. The pathogens patients carry have long been known to cause hospital-acquired infections, especially for the weak and immunocompromised. Having a rapid non-antibiotic approach to decolonizing the nose – a major source of infection transmission
Mater Hospital, North Sydney has become the first Australian hospital to use Ondine Biomedical's award-winning light-activated antimicrobial technology Ondine Biomedical Inc. (LON: OBI), the Canadian life sciences company pioneering light-activated antimicrobial treatments, announces that Mater Hospital, North Sydney, a private hospital in New South Wales, has become the first Australian hospital to start using its light-activated antimicrobial Steriwave® technology to prevent the spread of hospital-acquired infections (HAIs). Mater Hospital, located in North Sydney and founded in 1906, is part of St. Vincent's Health Australia Group, Australia's largest not-for-profit provider of health and aged care services.
Medical Oncologist, Professor Frances Boyle AM, Director of the Patricia Ritchie Centre for Cancer Care and Research at Mater Hospital and Professor of Medical Oncology at the University of Sydney, said: "We are very pleased to be the first hospital in Australia to have the Steriwave nasal decolonization system. The pathogens patients carry have long been known to cause hospital-acquired infections, especially for the weak and immunocompromised. Having a rapid non-antibiotic approach to decolonizing the nose – a major source of infection transmission – is a benefit to our patients." Orthopaedic Spine Surgeon Dr John Street, Director of the Integrated Ambulatory Spine Program at Vancouver Coastal Health and upcoming President of the Canadian Spine Society, was a keynote speaker at the recent 2024 Spine Society of Australia 35th Annual Scientific Meeting
Re-rating is justified. Am thinking of 20p initially.
Expect results to be substantial - but realistic
Yes - As usual we remain totally under the radar, but this will not always be the case.
We are now in Australia, so that is something new, and gradually Steriwave will gain recognition throughout the World.
Currently
Not long to wait for results now
Ondine Biomedical Inc on Monday announced that Steriwave has been used for the first time in an Australian hospital.
The Vancouver-based life sciences company said that Mater Hospital in North Sydney has become the first Australian hospital to start using Steriwave for the prevention of hospital-acquired infections.
Medical Oncologist Frances Boyle said: "We are very pleased to be the first hospital in Australia to have the Steriwave nasal decolonization system. The pathogens patients carry have long been known to cause hospital-acquired infections, especially for the weak and immunocompromised. Having a rapid non-antibiotic approach to decolonizing the nose - a major source of infection transmission - is a benefit to our patients."
Steriwave is a light-activated antimicrobial which employs patented nasal photodisinfection technology to eliminate bacteria, fungi and viruses located on human tissues.
According to Ondine, surgical site infections are "one of the most significant complications in cardiac surgery patients and are strongly associated with poorer prognosis".
This comes after Ondine announced earlier this month that Steriwave had been approved by HCA Healthcare UK for use in its healthcare facilities.
Is that the results will be out in the beginning of May.
They will show the increase in commercializing during 2023,
and show more movement towards profit.
The impression I get is that great strides have been made,
and will show how undervalued the SP has been, and show
that a re-rating is justified. Am thinking of 20p initially.
Also expect a larger company may move to take-over.
imho- dyor
Https://www.britishbulls.com/SignalPage.aspx?lang=en&Ticker=dest.L
Https://www.britishbulls.com/SignalPage.aspx?lang=en&Ticker=gsf.L
Https://www.britishbulls.com/SignalPage.aspx?lang=en&Ticker=groc.L
One can imagine the impact on revenue of Ondine as Steriwave gains recognition in hospitals throughout the world which adopt it as the preferred method to achieve huge reductions in fatalities
The resultant share price achievement, which is currently tiny, would be significant
Thank you for your note, Peter. We recognize that there are questions and are working to address this issue.
Https://www.britishbulls.com/SignalPage.aspx?lang=en&Ticker=obi.L
6.53-6.8p current low price
Entry into ICU market expands revenue potential
Following interest from Canadian Hospitals, Ondine prepares to enter the Intensive Care Unit (ICU) market
· Treatment of patients in ICUs would significantly expand Ondine's
potential market opportunity.
· Hundreds of thousands of patients are admitted to the ICU every year
in Canada alone, with an average stay of over four days.
6.655-7.08 current price
in my opinion this has to be a steal
Ondine Biomedical Inc on Monday reported that a study undertaken at the Mazankowski Alberta Heart Institute demonstrated a 32% reduction in cardiac surgical site infections through the use of its Steriwave product as a replacement for the antibiotic Mupirocin.
This comes after Steriwave was implemented on a pilot basis as a replacement for Mupirocin in June last year, the Vancouver-based life sciences company said.
Steriwave is a light-activated antimicrobial which employs patented nasal photodisinfection technology to eliminate bacteria, fungi and viruses located on human tissues.
According to Ondine, SSIs are "one of the most significant complications in cardiac surgery patients and are strongly associated with poorer prognosis".
Just last week, Ondine announced that Steriwave had been approved by HCA Healthcare UK for use in its healthcare facilities.
Shares in Ondine were up 1.0% at 7.57 pence each in London on Monday afternoon.
One can imagine the impact on revenue as it gains total acceptance as the way to achieve huge reductions in fatalities.
The resultant revenue of Ondine steriwave would be huge as hospitals throughout the world use it as the preferred method.